What is LLY's House Rating?

LLY scores 59 out of 100 (grade C) as of 2026-10-16, ranking #10 of 150 Health Care stocks we cover.

What do analysts say about LLY?

ThetaGrade's analyst-sentiment pillar for LLY scores 50/100 against its sector peers, which we read as mixed. This is our own derived score; we do not republish individual analyst ratings, counts or targets.

When does LLY report earnings next?

LLY's next earnings report is estimated for about 2026-10-29 (window 2026-10-26 to 2026-11-01), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.

ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.

LLY Lilly (Eli)

Health Care · Pharmaceuticals · close $1257.03 (2026-10-16) · latest quarter in EDGAR: 2026-06-30

#10/150 in sector · #75/964 overall

Lilly (Eli) (LLY) has a ThetaGrade House Rating of 59/100 (grade C), ranking #10 of 150 in Health Care. Its strongest pillars are profitability (84) and growth (73); its weakest is valuation (22). TTM revenue growth is 49.6% and operating margin 43.3%.

Data as of 2026-10-16.

Analyst sentiment

weight 7.5% · 50

Consensus score (1–5) (3.8%)	derived	60
90-day net rating shift (3.8%)	derived	29

Growth

weight 30.83% · 73

Revenue growth YoY (TTM) (12.3%)	49.6%	88
EPS growth YoY (TTM) (12.3%)	94.8%	89
Revenue acceleration (6.2%)	-7.9%	10

Profitability

weight 18.5% · 84

Operating margin (9.9%)	43.3%	98
4Q gross-margin change (8.6%)	0.8%	67

Balance sheet

weight 18.5% · 53

Net debt / EBITDA (9.9%)	1.07×	55
Current ratio (4.9%)	1.35	22
Interest coverage (3.7%)	38.54×	89

Cash flow

weight 12.33% · 43

FCF margin (6.2%)	13.8%	55
FCF yield (6.2%)	0.8%	30

Valuation

weight 12.33% · 22

P/E (inverted) (6.2%)	42.18×	28
EV/Sales (inverted) (6.2%)	15.34×	16

Technicals (EOD)

RSI(14)	68.6
EMA 9 / 21	1205.28 / 1184.95
200-day SMA	1079.91
Volume vs 20d avg	1.00×
20-day return	9.1%

Exit-rule monitor

EXITRating break: House Rating below 60

Data source per metric (SEC XBRL tag or derivation): Revenue: Revenues · Gross profit: Revenue − CostOfGoodsAndServicesSold · Operating income: Pretax income + fiscal-year interest expense (EBIT proxy) · Interest expense: InterestExpenseNonoperating · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).

Get rating changes like LLY's in the free Daily Brief

The market’s key events and signals, digested before the open.

✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
✓ OPEX, FOMC, CPI and jobs-day reminders

Free. Want more? See Premium (waitlist).

FAQ

What is LLY's House Rating?: LLY scores 59 out of 100 (grade C) as of 2026-10-16, ranking #10 of 150 Health Care stocks we cover.
What do analysts say about LLY?: ThetaGrade's analyst-sentiment pillar for LLY scores 50/100 against its sector peers, which we read as mixed. This is our own derived score; we do not republish individual analyst ratings, counts or targets.
When does LLY report earnings next?: LLY's next earnings report is estimated for about 2026-10-29 (window 2026-10-26 to 2026-11-01), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
Is LLY a buy?: ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.

Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology